Invion

Subscribe to receive announcements and updates from Invion.

New investors

Home

Announcements

Updates

Lato

upload.jpg

The University of Pennsylvania Perelman School of Medicine (Penn Medicine) is actively researching and using PhotodynamicTherapy (PDT). Invion had a productive meeting last week with PDT experts from the Abramson Cancer Center Clinical Research at Penn Medicine, University of Pennsylvania Health System. 

Exec Chair and CEO, Prof Thian Chew and Invion’s Scientific Advisor, Prof Rob Ramsay, met with Professors Keith Cengel, Director, Photodynamic Therapy Program, and Theresa Busch,  Associate Director of Radiation Biology Division. Both professors are  heavily involved in researching PDT and have written papers on the  therapy.


Invion  is exploring opportunities for collaboration with world leading  research institutions. Penn Medicine currently offers PDT as an  alternative for certain types of cancers. For more info on these  treatments at Penn Medicine: https://www.pennmedicine.org/cancer/navigating-cancer-care/treatment-types/radiation/photodynamic-therapy.

PDT has been around for decades and there are some US FDA approved PDT treatments. Despite this, PDT is not  mainstream or even on the radar of most patients and clinicians. Invion  hopes to change this as Photosoft is the next-gen PDT with the potential to overcome several of the shortcomings of current PDT treatments and improve efficacy.

Invion Meets with PDT experts from University of Pennsylvania